- $3.34bn
- $4.62bn
- $2.38bn
- 78
- 53
- 73
- 77
Annual income statement for ICU Medical, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1,271 | 1,316 | 2,280 | 2,259 | 2,382 |
Cost of Revenue | |||||
Gross Profit | 461 | 491 | 698 | 740 | 825 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 1,173 | 1,193 | 2,323 | 2,236 | 2,339 |
Operating Profit | 98.2 | 123 | -42.9 | 22.8 | 43 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 97.5 | 123 | -114 | -78.3 | -66 |
Provision for Income Taxes | |||||
Net Income After Taxes | 86.9 | 103 | -74.3 | -29.7 | -118 |
Net Income Before Extraordinary Items | |||||
Net Income | 86.9 | 103 | -74.3 | -29.7 | -118 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 86.9 | 103 | -74.3 | -29.7 | -118 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 5.08 | 5.5 | -1.1 | -0.114 | -3.19 |